• The technology described in this briefing is OxyMask. It is used for delivering oxygen therapy.

  • The innovative aspect is the novel design, which is intended to improve the efficiency and convenience of oxygen therapy.

  • The intended place in therapy is uncertain because of the wide range of settings and clinical conditions in which oxygen therapy is prescribed. Specialist commentators suggested that it might be particularly suitable for people who need varying flow rates.

  • The main points from the evidence summarised in this briefing are from 3 studies in the US and Canada. Based on small numbers of patients, they suggest that OxyMask is at least as effective at delivering oxygen as a non-rebreather mask or a venturi mask.

  • Key uncertainties are that the evidence base is still developing and currently lacks quantity and quality. Further studies comparing oxygen use and patient experience of OxyMask with current masks in NHS oxygen therapy pathways would be particularly valuable. There are no published studies in children.

  • The price of OxyMask is £2.40 per unit. Current oxygen masks range from £0.41 to £1.31 (both excluding VAT). Using OxyMask would be more expensive than current masks but this may be offset if less oxygen is needed to deliver the needed oxygen concentration.